Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. Part of the decline followed the threat of devastating the large drug creators and developers by lowering the high prices of drugs. Amgen’s stock loss can also be attributed to the pressure exerted by negative investors on the stock.
Today, after . . .